[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"acute-limb-ischemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:acute-limb-ischemia":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,63,98,127,147],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":34,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100618724","case-specific-health-care-professional-clinical-survey-of-liberant-thrombectomy-system-100618724",false,"NCT07335341","Case-Specific Health Care Professional Clinical Survey of Liberant™ Thrombectomy System","Patient case selection to be included in the clinical assessment will be specific to Liberant and will be made according to the following criteria:\n\n1. Patient treated is age ≥ 22 years at the time of procedure\n2. Use of Liberant in accordance with the device labeling within 72 hours of index procedure","ALL","22 Years",{"count":18,"type":19},50,"ESTIMATED","OBSERVATIONAL","The purpose of Case-Specific Health Care Professional (HCP) Clinical Survey of Liberant™ Thrombectomy System, also known as the Liberant Clinical Assessment, is to collect first-in-human clinical data to confirm the safety and performance of the Medtronic Liberant™ thrombectomy system when used for the removal of fresh, soft emboli or thrombi from the vessels of the peripheral arterial and venous systems",[23,24,25,26,27,28,29,30,31,32,33],"Venous Embolism of Lower Extremities (Diagnosis)","Arterial Embolism and Thrombosis","Acute DVT of Lower Extremity","Chronic DVT of Lower Extremity","DVT","Deep Vein Thrombosis Leg","Thrombus in the Peripheral Venous Vasculature","Peripheral Arterial Disease","Acute Limb Ischemia","Lower Extremity Acute Limb Ischemia","LE ALI",[35,36,37,38,39,40,41,42,43,30,44,45,46,47,48,49],"Thrombus in Peripheral Arterial Systems","Thrombectomy","Thrombosis","Venous Thrombosis","Aspiration Thrombectomy","Percutaneous Mechanical Thrombectomy","Arterial Occlusive Diseases","Vascular Diseases","Peripheral Vascular Diseases","Mechanical Thrombectomy","Aspiration","Liberant Thrombectomy System","adverse events","Excipio","Thrombus in Peripheral Venous Systems","RECRUITING","2026-06-05",{"date":53,"type":54},"2026-06-08","ACTUAL",{"date":56,"type":54},"2026-02-24",{"date":58,"type":19},"2026-10",{"name":60,"class":61},"Medtronic Endovascular","INDUSTRY",2,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":15,"minAge":70,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":82,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":97},"100630068","routine-versus-provisional-distal-perfusion-catheter-placement-in-patients-undergoing-mechanical-circulatory-support-100630068","NCT07482865","Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support","PERFUSE-MCS","Inclusion Criteria:\n\n* Patients aged 19 years old\n* Cardiogenic shock requiring mechanical circulatory support through femoral artery approach\n* Subject who can verbally confirm understandings of risks and benefits of receiving distal perfusion catheter insertion and he\u002Fshe or his\u002Fher legally authorized representative provides written informed consent prior to any study related procedure.\n* Under the critically-ill clinical circumstance (unclear consciousness of patient), legally authorized representative can provide written informed consent prior to any study related procedure.\n\nExclusion Criteria:\n\n* Apparent symptoms and sign of acute limb ischemia immediately after mechanical circulatory support insertion\n* Significant coagulopathy precluding invasive procedure due to high risk of bleeding\n* Pregnant women, women with potential childbearing, or lactating women\n* Irreversible limb ischemia requiring interventional procedures or surgery at the time of MCS insertion\n* Previous history if femoral-femoral bypass grafting or femoral-popliteal bypass grafting\n* Previous history of limb amputation\n* Unwilling or unable to obtain informed consent from the participant or legally authorized representative","19 Years",{"count":72,"type":19},500,"INTERVENTIONAL",[75],"NA","A prospective, multi-center, open label, randomized controlled, superiority trial to compare clinical outcomes between routine distal perfusion catheter (DPC) insertion versus provisional distal perfusion catheter (DPC) insertion in the occurrence of sign or symptom of acute limb ischemia in patients undergoing mechanical circulatory support (MCS) through femoral artery approach.",[78,79,80,81,31],"Cardiogenic Shock","Acute Myocardial Infarction of Inferior Wall","Congestive Heart Failure","Myocarditis",[78,83,84,80,85],"Distal perfusion catherter","Acute Myocardial Infarction","Limb ischemia","NOT_YET_RECRUITING","2026-03-18",{"date":89,"type":54},"2026-03-20",{"date":91,"type":19},"2026-05-01",{"date":93,"type":19},"2030-10-31",{"name":95,"class":96},"Samsung Medical Center","OTHER",6,{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":15,"minAge":106,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":73,"phases":109,"briefSummary":111,"conditions":112,"keywords":113,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":126},"100467895","phase-3-thrombolysis-with-recombinant-non-immunogenic-staphylokinase-vs-surgery-in-patients-with-acute-limb-ischemia-forat-trial-100467895","NCT05372718","Thrombolysis With Recombinant Non-immunogenic Staphylokinase vs Surgery in Patients With Acute Limb Ischemia FORAT Trial","Multicenter, Open-label, Randomized Clinical Trial of Efficacy and Safety of the Thrombolysis With Recombinant Non-immunogenic Staphylokinase (Fortelyzin®) in Patients With ALI vs Surgery","FORAT","Inclusion Criteria:\n\n* Men and women aged 18 and older;\n* Diagnosis of I-II b degree of ALI;\n* Patient consent to use reliable contraceptive methods throughout the study and for 3 weeks after:\n\n  * women who have a negative pregnancy test and use the following contraceptives: intrauterine devices, oral contraceptives, contraceptive patch, prolonged injectable contraceptives, double barrier method of contraception. Women who are not fertile can also take part in the study (documented conditions: hysterectomy, tubal ligation, infertility, menopause for more than 1 year);\n  * men using barrier contraception. The study may also involve men who are not fertile (documented conditions: vasectomy, infertility);\n* Availability of signed and dated informed consent of the patient to participate in the study.\n\nExclusion Criteria:\n\n* Extensive bleeding at present;\n* Intracranial (including subarachnoid) hemorrhage at present;\n* Recent gastrointestinal bleeding (within 10 days);\n* Major surgery or major trauma within the previous 3 months, recent traumatic brain injury;\n* Systolic blood pressure above 180 mm Hg or diastolic blood pressure above 110 mm Hg or the need for intravenous drugs to lower blood pressure to these limits;\n* Pregnancy, lactation;\n* Known hypersensitivity to Fortelyzin®;\n* Platelet count less than 100,000\u002FµL","18 Years",{"count":108,"type":19},170,[110],"PHASE3","Objective: to evaluate the efficacy and safety of intra-arterial intrathrombus administration of the recombinant non-immunogenic staphylokinase (Fortelyzin®) in patients with acute limb ischemia (ALI) vs surgery.",[31],[114,115,116],"acute limb ischemia","thrombolysis","thrombosis","2025-11-27",{"date":119,"type":54},"2025-12-01",{"date":121,"type":54},"2022-12-26",{"date":123,"type":19},"2026-12-31",{"name":125,"class":61},"Supergene, LLC",8,{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":132,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":15,"minAge":106,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":146},"100505959","pounce-thrombectomy-system-retrospective-registry-100505959","NCT05868161","Pounce™ Thrombectomy System Retrospective Registry","PROWL","Inclusion Criteria:\n\n* Subject underwent an endovascular intervention where the Pounce Thrombectomy System was attempted\n* Subject is willing and able to provide informed consent prior to the collection of study data or a consent waiver is in place\n\nExclusion Criteria:\n\n* Subject is under the age of 18 years",{"count":72,"type":19},"The PROWL registry is an open-label retrospective, multi-center, US study of the Surmodics™ Pounce™ Thrombectomy System for the non-surgical removal of emboli and thrombi in the peripheral arterial vasculature.",[30,31],"2025-09-04",{"date":139,"type":54},"2025-09-11",{"date":141,"type":54},"2023-04-18",{"date":143,"type":19},"2026-07-31",{"name":145,"class":61},"SurModics, Inc.",9,{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":153,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":15,"minAge":4,"maxAge":4,"enrollmentInfo":155,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":157,"conditions":158,"keywords":4,"overallStatus":86,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":4},"100583888","ali-in-cancer-patients-100583888","NCT06882187","ALI in Cancer Patients","Outcomes of Acute Limb Ischemia in Cancer Patients .","ALI","Inclusion Criteria:\n\n* All cancer patient presented to Vascular and Endovascular surgery departement with ALI.\n\nExclusion Criteria:\n\n* Patients with benign tumors or without active malignancy.\n* Patients with iatrogenic limb ischemia related to a tumor chemoembolization procedure.",{"count":156,"type":19},40,"The aim of the study is to describe and evaluate the outcomes of cancer patients presenting with and treated for ALI at our center .",[31],"2025-03-12",{"date":161,"type":54},"2025-03-18",{"date":163,"type":19},"2025-05-01",{"date":165,"type":19},"2026-07-01",{"name":167,"class":96},"Assiut University"]